Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.46 |
| ▸ | RELA | Q04206 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.45 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7755640 | 0.87 | ALDH1A1 (0.53) | HAO1ALDH1A1SMN1; SMN2MAPTHDAC8 | |
| SCHEMBL11822677 | 0.87 | ALDH1A1 (0.53) | HAO1ALDH1A1SMN1; SMN2MAPTHDAC8 | |
| SCHEMBL11567237 | 0.87 | HAO1 (0.66) | HAO1ALDH1A1SMN1; SMN2MAPTHDAC8 | |
| SCHEMBL17259217 | 0.86 | HAO1 (0.66) | HAO1ALDH1A1SMN1; SMN2MAPTHDAC8 | |
| SCHEMBL11829139 | 0.86 | ALDH1A1 (0.51) | HAO1ALDH1A1SMN1; SMN2MAPTHDAC8 | |
| SCHEMBL4485834 | 0.85 | ALDH1A1 (0.47) | HAO1ALDH1A1SMN1; SMN2MAPTLMNA | |
| SCHEMBL4937649 | 0.85 | ALDH1A1 (0.47) | HAO1ALDH1A1SMN1; SMN2MAPTLMNA | |
| SCHEMBL7049040 | 0.84 | ALDH1A1 (0.62) | HAO1ALDH1A1SMN1; SMN2MAPTHDAC8 | |
| SCHEMBL7049036 | 0.84 | ALDH1A1 (0.62) | HAO1ALDH1A1SMN1; SMN2MAPTHDAC8 | |
| SCHEMBL1789154 | 0.82 | ALDH1A1 (0.63) | HAO1ALDH1A1SMN1; SMN2MAPTHDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230002396-A1 | THERAPEUTIC COMPOUNDS | GENENTECH, INC. (US) | 2023-01-05 | — | — | US | disclosed |
| US-20230002396-A1 | THERAPEUTIC COMPOUNDS | GENENTECH, INC. (US) | 2023-01-05 | — | — | US | disclosed |
| EP-4065230-A1 | THERAPEUTIC COMPOUNDS | Genentech, Inc. (US) | 2022-10-05 | — | — | EP | disclosed |
| CN-114786778-A | Therapeutic compounds | 基因泰克公司 | 2022-07-22 | — | — | CN | disclosed |
| WO-2021108483-A1 | THERAPEUTIC COMPOUNDS | GENENTECH, INC. (US) | 2021-06-03 | — | — | WO | disclosed |
| EP-1339690-B1 | N-TYPE CALCIUM CHANNEL ANTAGONISTS FOR THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2009-01-21 | — | — | EP | disclosed |
| US-7348340-B2 | N-type calcium channel antagonists for the treatment of pain | ASTRAZENECA AB (SE) | 2008-03-25 | — | — | US | disclosed |
| US-20070129363-A1 | N-TYPE CALCIUM CHANNEL ANTAGONISTS FOR THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2007-06-07 | — | — | US | disclosed |
| US-7189714-B2 | N-type calcium channel antagonists for the treatment of pain | ASTRAZENECA AB (SE) | 2007-03-13 | — | — | US | disclosed |
| EP-1339706-B1 | N-TYPE CALCIUM CHANNEL ANTAGONISTS FOR THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2006-04-19 | — | — | EP | disclosed |
| US-20040053964-A1 | N-type calcium channel antagonists for the treatment of pain | ASTRAZENECA AB (SE) | 2004-03-18 | — | — | US | disclosed |
| US-20040053965-A1 | N-type calcium channel antagonists for the treatment of pain | ASTRAZENECA AB (SE) | 2004-03-18 | — | — | US | disclosed |
| EP-1339706-A1 | N-TYPE CALCIUM CHANNEL ANTAGONISTS FOR THE TREATMENT OF PAIN | AstraZeneca AB (SE) | 2003-09-03 | — | — | EP | disclosed |
| EP-1339688-A1 | N-TYPE CALCIUM CHANNEL ANTAGONISTS FOR THE TREATMENT OF PAIN | AstraZeneca AB (SE) | 2003-09-03 | — | — | EP | disclosed |
| EP-1339690-A1 | N-TYPE CALCIUM CHANNEL ANTAGONISTS FOR THE TREATMENT OF PAIN | AstraZeneca AB (SE) | 2003-09-03 | — | — | EP | disclosed |
| EP-1339689-A1 | N-TYPE CALCIUM CHANNEL ANTAGONISTS FOR THE TREATMENT OF PAIN | AstraZeneca AB (SE) | 2003-09-03 | — | — | EP | disclosed |
| WO-2002036568-A1 | N-TYPE CALCIUM CHANNEL ANTAGONISTS FOR THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2002-05-10 | — | — | WO | disclosed |
| WO-2002036567-A1 | N-TYPE CALCIUM CHANNEL ANTAGONISTS FOR THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2002-05-10 | — | — | WO | disclosed |
| WO-2002036569-A1 | N-TYPE CALCIUM CHANNEL ANTAGONISTS FOR THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2002-05-10 | — | — | WO | disclosed |
| WO-2002036586-A1 | N-TYPE CALCIUM CHANNEL ANTAGONISTS FOR THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2002-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053964-A1 | N-type calcium channel antagonists for the treatment of pain | CACNA1E, CACNA1B, CACNA1A | HAO1 2920/4885ALDH1A1 2325/4885SMN1; SMN2 609/4885 |
| US-20040053965-A1 | N-type calcium channel antagonists for the treatment of pain | CACNA1B, CACNA1E, CACNA1A | HAO1 3256/4885ALDH1A1 2904/4885SMN1; SMN2 242/4885 |
| US-20070129363-A1 | N-TYPE CALCIUM CHANNEL ANTAGONISTS FOR THE TREATMENT OF PAIN | CACNA1B, CACNA1E, CACNA1G | HAO1 3472/4885ALDH1A1 3919/4885SMN1; SMN2 480/4885 |
| US-20230002396-A1 | THERAPEUTIC COMPOUNDS | YAP1, YES1, TEAD2 | HAO1 4211/4885ALDH1A1 3527/4885SMN1; SMN2 1111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.